Biora Therapeutics, Inc. (BIOR)
USD 0.22
(0.0%)
USD 0.22
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 132.63 Million USD | -14.87% |
| 2022 | 155.81 Million USD | -19.61% |
| 2021 | 193.81 Million USD | -25.86% |
| 2020 | 261.43 Million USD | 40.86% |
| 2019 | 185.6 Million USD | 21.02% |
| 2018 | 153.36 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 107.58 Million USD | -12.66% |
| 2024 Q1 | 123.17 Million USD | -7.13% |
| 2023 Q2 | 170.55 Million USD | 7.78% |
| 2023 FY | 132.63 Million USD | -14.87% |
| 2023 Q4 | 132.63 Million USD | -13.59% |
| 2023 Q3 | 153.48 Million USD | -10.01% |
| 2023 Q1 | 158.24 Million USD | 1.56% |
| 2022 Q3 | 160.05 Million USD | -7.59% |
| 2022 Q2 | 173.2 Million USD | -3.73% |
| 2022 Q1 | 179.92 Million USD | -7.17% |
| 2022 FY | 155.81 Million USD | -19.61% |
| 2022 Q4 | 155.81 Million USD | -2.65% |
| 2021 Q2 | 259.55 Million USD | 2.15% |
| 2021 Q1 | 254.08 Million USD | -2.81% |
| 2021 FY | 193.81 Million USD | -25.86% |
| 2021 Q3 | 274.64 Million USD | 5.81% |
| 2021 Q4 | 193.81 Million USD | -29.43% |
| 2020 Q3 | 180.03 Million USD | -11.56% |
| 2020 Q4 | 261.43 Million USD | 45.21% |
| 2020 Q2 | 203.57 Million USD | 4.0% |
| 2020 Q1 | 195.74 Million USD | 5.47% |
| 2020 FY | 261.43 Million USD | 40.86% |
| 2019 FY | 185.6 Million USD | 21.02% |
| 2019 Q3 | 185.16 Million USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 Q4 | 185.6 Million USD | 0.23% |
| 2018 FY | 153.36 Million USD | 0.0% |
| 2018 Q4 | 153.36 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -2648.953% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -5482.323% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -240.73% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -4672.796% |
| Better Therapeutics, Inc. | 23.84 Million USD | -456.312% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -1501.111% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -1229.791% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -403.573% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -317.317% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -91.027% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -1569.304% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -175.687% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 15.694% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -3683.162% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -523.003% |
| Molecular Templates, Inc. | 31.17 Million USD | -325.511% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -959.823% |
| NexImmune, Inc. | 5.08 Million USD | -2508.772% |
| Orgenesis Inc. | 35.53 Million USD | -273.255% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -703.27% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -49685.672% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -5678.51% |
| Scopus BioPharma Inc. | 7.45 Million USD | -1679.29% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 73.178% |
| Statera Biopharma, Inc. | 22.67 Million USD | -484.906% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -1115.283% |
| Trevena, Inc. | 48.26 Million USD | -174.825% |
| Vaxxinity, Inc. | 30.94 Million USD | -328.632% |
| Vaccinex, Inc. | 5.94 Million USD | -2132.178% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -6638.48% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -245.649% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -4702.941% |